Ginkgo Bioworks Holdings Inc
DNA
Company Profile
Business description
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering and BiosecurityThe majority of revenue in the company comes from the Biosecurity segment, which charges fees for data analytics and services.
Contact
27 Drydock Avenue
8th Floor
BostonMA02210
USAT: +1 877 422-5362
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
1,218
Stocks News & Analysis
stocks
Is this ASX share a long-term buy?
Current operating conditions are challenging but over the long-term prospects are better.
stocks
Why Guzman and Reece's share reversals have a lot in common
Investors must weigh exciting growth stories against competitive dynamics and the price they are being asked to pay.
stocks
Going into earnings, is Nvidia stock a buy, a sell, or fairly valued?
Watching the data centre business and the debate around it, here’s what we think of Nvidia stock.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,477.30 | 20.70 | -0.24% |
| CAC 40 | 8,141.19 | 90.12 | 1.12% |
| DAX 40 | 22,790.56 | 380.29 | 1.70% |
| Dow JONES (US) | 43,810.49 | 189.33 | 0.43% |
| FTSE 100 | 8,732.37 | 63.70 | 0.73% |
| HKSE | 23,787.93 | 753.91 | 3.27% |
| NASDAQ | 19,269.50 | 243.11 | 1.28% |
| Nikkei 225 | 38,142.37 | 95.42 | -0.25% |
| NZX 50 Index | 12,452.46 | 145.19 | 1.18% |
| S&P 500 | 6,007.46 | 52.21 | 0.88% |
| S&P/ASX 200 | 8,240.70 | 11.20 | -0.14% |
| SSE Composite Index | 3,380.21 | 34.17 | 1.02% |